Sangamo showcases progress in our pre-clinical programs at ASGCT.
Click here to view
Science
Overview
Zinc Fingers
Cell Therapy
Genome Regulation
Bioethics
Publications
Presentations
Manufacturing Capabilities
Programs
Programs
Pipeline
Clinical Trials
Collaborations
Patients
Our Commitment
Patient Stories
Bioethics
Resources
Investors & Media
Overview
News Releases
Events
Presentations
ESG
Careers
Core Values
Open Positions
Culture
Employee Benefits
About
Inside Sangamo
Latest News
Connect
Science
Overview
Zinc Fingers
Cell Therapy
Genome Regulation
Bioethics
Publications
Presentations
Manufacturing Capabilities
Programs
Programs
Pipeline
Clinical Trials
Collaborations
Patients
Our Commitment
Patient Stories
Bioethics
Resources
Investors & Media
Overview
News Releases
Events
Presentations
ESG
Careers
Core Values
Open Positions
Culture
Employee Benefits
About
Inside Sangamo
Latest News
Connect
LinkedIn
Twitter
AAV
Resolution of hepatic fibrosis after zinc-finger nuclease-mediated gene editing in the PiZ mouse model of human alpha-1-antitrypsin deficiency liver disease
March 7th, 2023
First-in-human in vivo genome editing via AAV-zinc finger nucleases for mucopolysaccharidosis I/II and
hemophilia B
November 1st, 2022
Overview of Analytics Needed to Support a Robust Gene Therapy Manufacturing Process
January 19th, 2022
Anion-Exchange HPLC Assay for Separation and Quantification of Empty and Full Capsids in Multiple Adeno-Associated Virus Serotypes
April 23rd, 2021
AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction
August 3rd, 2020